RiverVest is a leading venture capital firm building life science companies
to address significant unmet needs of patients and deliver consistently strong returns to investors.
Bonum Therapeutics Appoints Samuel C. Blackman, MD, PhD, to its Board of Directors – 12/3/2024
Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody BJT-778 Achieved 100% Virologic Response and Up To 78% Combined Virologic Response and ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D (CHD) – 11/15/2024
Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients with Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia or T Cell Lymphoblastic Lymphoma – 11/12/2024
Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs as the Company Embarks on a Pivotal Trial for its Investigational, Allogeneic CD7-Targeted CAR-T Cell Therapy- 11/12/2024
Glycomine Appoints Joshua Grass as Chairperson of Board of Directors- 10/10/2024
InterVene, Inc. Announces $13 Million Series A Financing to Advance Recana™ System Through US Market Clearance – 10/7/2024
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million – 10/4/2024
Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia – 9/18/2024
Glycomine Receives FDA Fast Track Designation for BLM101 for the Treatment of PMM2-CDG- 9/18/2024
Avalyn Announces Initiation of its Global Phase 2b MIST Study of AP01 Inhaled Pirfenidone for Progressive Pulmonary Fibrosis – 9/3/2024
Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Noval Inhaled Nintedanib – 8/12/2024
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors- 8/8/2024
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors- 8/5/2024
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older – 7/25/2024
Integrated DNA Technologies Announces New Licensing Agreement with SeQure Dx to Advance CRISPR-based Therapeutics – 7/15/2024
Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC – 7/8/2024
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies – 6/17/2024
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress – 6/14/2024
Bluejay Therapeutics Presents Positive Preliminary BJT-778 Data from Phase 2 Clinical Trial in Chronic Hepatitis D at EASL 2024 Congress – 6/5/2024
Bluejay Therapeutics Receives Positive Opinion on Orphan Designation from the European Medicines Agency for BJT-778 for the Treatment of Chronic Hepatitis D – 5/29/2024
Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June
– 5/20/2024
Biolinq Raises $58 Million to Advance Wearable Biosensors Through Pivotal Trial for Metabolic Health Using Precision Microsensor Technology
– 4/4/2024
Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection- 3/25/2024
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies – 3/19/2024
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis – 3/14/2024
Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG – 3/4/2024
Synthego and SeQure Dx Partner to Provide Comprehensive Off-Target Analysis Services for CRISPR-Based Therapeutics Developers – 1/23/2024
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia – 1/22/2024
Subscribe to our newsletter